latest news releases from the newsroom
ANSYS, Inc. Signs Definitive Agreement to Acquire Ansoft Corporation
SOUTHPOINTE, Pa. and PITTSBURGH, March 31, 2008 (PRIME NEWSWIRE) -- ANSYS, Inc. (Nasdaq:ANSS), a global innovator of simulation software and technologies designed to optimize product development processes, and Ansoft Corporation (Nasdaq:ANST), a global provider of Electronic Design Automation (EDA) software, announced today that they signed a definitive agreement whereby ANSYS will acquire Ansoft for a purchase price of approximately $832 million in a mix of cash and ANSYS common stock. The strategic, complementary business combination of ANSYS and Ansoft will create the leading provider of 'best-in-class' simulation capabilities, with combined trailing 12-month revenues of $485 million. When completed, ANSYS currently anticipates that the transaction will be modestly accretive to non-GAAP earnings per share in its first full year of combined operations.
MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
SAN DIEGO, March 31, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced the initiation of a Phase II clinical trial, by holding the Investigator's Meeting, to determine the safety and efficacy of MN-221 in patients with severe, acute exacerbations of asthma.